Suryavathi Viswanadhapalli

23PUBLICATIONS
117CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersReceptors and membrane biologyProteomics and intermolecular interactions (excl. medical proteomics)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Mar 28, 2026
Targeting LIPA with ERX-41 Induces ER Stress and Inhibits Tumor Progression in Inflammatory Breast Cancer.

Zenaida Fuentes, Gaurav Sharma, Bianca A Romo

|Feb 06, 2026
Therapeutic optimization of LIPA targeting to induce endoplasmic reticulum stress and cell death in ovarian cancer.

Suryavathi Viswanadhapalli, Tae-Kyung Lee, Scott Elmore

|Dec 30, 2025
The PELP1 Pathway and Its Importance in Cancer Treatment.

Khaled Mohamed Nassar, Panneerdoss Subbarayalu, Suryavathi Viswanadhapalli

|Dec 02, 2025
Antibody-Mediated Targeting of Secretory Protein SCUBE3 Suppresses Cancer Progression by Inhibiting Oncogenic Signaling and Inducing Antitumor Immunity.

Deepika Singh, Benjamin C Onyeagucha, Daisy Medina

|Oct 29, 2025
EC359 Enhances Trametinib Efficacy in Ras/Raf-Driven Ovarian Cancer by Suppressing LIFR Signaling.

William C Arnold, Durga Meenakshi Panneerdoss, Baskaran Subramani

|Oct 08, 2025
Ligand-receptor interactions induce and mediate regulatory functions of BATF3+ B cells.

Hui Yan, Rui Wang, Suryavathi Viswanadhapalli

Pageof 4

Frequent Collaborators

22 joint publications

Ratna K Vadlamudi

12 joint publications

Gangadhara R Sareddy

5 joint publications

Manjeet Rao

5 joint publications

Yidong Chen